MX2022000390A - Derivados macrociclicos espirociclicos como inhibidores de mcl-1. - Google Patents
Derivados macrociclicos espirociclicos como inhibidores de mcl-1.Info
- Publication number
- MX2022000390A MX2022000390A MX2022000390A MX2022000390A MX2022000390A MX 2022000390 A MX2022000390 A MX 2022000390A MX 2022000390 A MX2022000390 A MX 2022000390A MX 2022000390 A MX2022000390 A MX 2022000390A MX 2022000390 A MX2022000390 A MX 2022000390A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitors
- spirocycle
- macrocyclic
- derivatives
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a agentes farmacéuticos de fórmula (I) útiles para la terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185177 | 2019-07-09 | ||
| EP19218032 | 2019-12-19 | ||
| PCT/EP2020/069097 WO2021005043A1 (en) | 2019-07-09 | 2020-07-07 | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000390A true MX2022000390A (es) | 2022-02-10 |
Family
ID=71579568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000390A MX2022000390A (es) | 2019-07-09 | 2020-07-07 | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240067660A1 (es) |
| EP (1) | EP3997097B1 (es) |
| JP (1) | JP7573591B2 (es) |
| KR (1) | KR20220034136A (es) |
| CN (1) | CN114096546A (es) |
| AU (1) | AU2020309745A1 (es) |
| BR (1) | BR112022000251A2 (es) |
| CA (1) | CA3144558A1 (es) |
| ES (1) | ES2987630T3 (es) |
| MX (1) | MX2022000390A (es) |
| WO (1) | WO2021005043A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| JP7441947B2 (ja) | 2019-11-26 | 2024-03-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｍｃｌ１阻害剤を調製するためのプロセス及び中間体 |
| CN120590359A (zh) * | 2020-11-19 | 2025-09-05 | 吉利德科学公司 | 用于制备大环mcl1抑制剂的方法和中间体 |
| KR20230121806A (ko) * | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드 |
| US20250051359A1 (en) * | 2021-11-16 | 2025-02-13 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| EA036551B1 (ru) | 2016-04-22 | 2020-11-23 | Астразенека Аб | Макроциклические ингибиторы mcl1 для лечения рака |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| TW201904976A (zh) | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
| WO2019222112A1 (en) | 2018-05-14 | 2019-11-21 | Gilead Sciences, Inc. | Mcl-1 inhibitors |
| AU2019374907A1 (en) | 2018-11-09 | 2021-06-03 | Prelude Therapeutics, Incorporated | Spiro-sulfonamide derivatives as inhibitors of Myeloid Cell Leukemia-1 (Mcl-1) protein |
-
2020
- 2020-07-07 ES ES20739606T patent/ES2987630T3/es active Active
- 2020-07-07 WO PCT/EP2020/069097 patent/WO2021005043A1/en not_active Ceased
- 2020-07-07 KR KR1020227003256A patent/KR20220034136A/ko not_active Withdrawn
- 2020-07-07 CA CA3144558A patent/CA3144558A1/en active Pending
- 2020-07-07 EP EP20739606.0A patent/EP3997097B1/en active Active
- 2020-07-07 US US17/624,949 patent/US20240067660A1/en not_active Abandoned
- 2020-07-07 CN CN202080050978.2A patent/CN114096546A/zh active Pending
- 2020-07-07 BR BR112022000251A patent/BR112022000251A2/pt unknown
- 2020-07-07 AU AU2020309745A patent/AU2020309745A1/en not_active Abandoned
- 2020-07-07 JP JP2022500888A patent/JP7573591B2/ja active Active
- 2020-07-07 MX MX2022000390A patent/MX2022000390A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022540825A (ja) | 2022-09-20 |
| ES2987630T3 (es) | 2024-11-15 |
| US20240067660A1 (en) | 2024-02-29 |
| AU2020309745A1 (en) | 2022-03-03 |
| JP7573591B2 (ja) | 2024-10-25 |
| KR20220034136A (ko) | 2022-03-17 |
| EP3997097A1 (en) | 2022-05-18 |
| CN114096546A (zh) | 2022-02-25 |
| EP3997097C0 (en) | 2024-03-20 |
| EP3997097B1 (en) | 2024-03-20 |
| CA3144558A1 (en) | 2021-01-14 |
| WO2021005043A1 (en) | 2021-01-14 |
| BR112022000251A2 (pt) | 2022-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ775660A (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
| NZ784224A (en) | Parp1 inhibitors | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| ZA202003554B (en) | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer | |
| MX2023000438A (es) | Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1. | |
| SG10201810401RA (en) | Pharmaceutical combinations for treating cancer | |
| PH12018501567A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| MX2020010942A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX393711B (es) | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
| MX2024004874A (es) | Compuestos heterociclicos para uso en el tratamiento de cancer. | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. | |
| MX2022015005A (es) | Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1. | |
| MX2022010299A (es) | Derivados macrocíclicos de indol como inhibidores de mcl-1. | |
| MX2022006180A (es) | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. | |
| MY206632A (en) | Pyridopyrimidines as histamine h4-receptor inhibitors |